US Patent 11608380 Anti-EGFRvIII antibodies and uses thereof
Patent 11608380 was granted and assigned to Regeneron Pharmaceuticals on March, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2023
Golden AI
Edits made to:
Infobox (+7 properties)
Infobox
Patent Inventor Names
Douglas MacDonald0
Frank Delfino0
Gavin Thurston0
Jessica R. Kirshner0
Joel H. Martin0
Marcus Kelly0
Thomas Nittoli0
Edits on 23 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 22 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 11 Apr, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+532 characters)
US Patent 11608380 Anti-EGFRvIII antibodies and uses thereof
Article
The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116083800
Date of Patent
March 21, 2023
0Patent Application Number
169186560
Date Filed
July 1, 2020
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11608380 Anti-EGFRvIII antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
